You are here: Home » News-IANS » Health-Medicine
Business Standard

Novel drug may help tackle treatment-resistant cancers

IANS  |  New York 

A new class of drug that has the potential to help patients, especially those suffering from breast and who no longer respond to existing therapies has been discovered.

Breast patients frequently become resistant to existing treatments, leading to the becoming fatal.

Early lab-based tests of a drug named were successful in targeting resistant breast and indicated minimal side effects.

"represent a significant threat for patients, as once a cancer stops responding to treatments there is increasingly little clinicians can do," said Charles Coombes, at

"Drugs such as these could help to shift the balance back in favour of the patients, potentially providing a new option to patients for who existing treatments no longer work," Coombes added.

The findings, published in the journal Molecular Cancer Therapeutics, noted that the drug targets an enzyme called CDK7 -- involved in directing cells through their lifecycle, which consists of growth, DNA replication and cell division.

CDK7 is also involved in the process of transcription -- a vital step in -- the creation of proteins to carry out cell functions.

Particular cancers, such as treatment-resistant breast cancers, have a unique dependence on transcription, meaning targeting CDK7 may be particularly effective.

By inhibiting transcription, shuts down the ability of the cancer to spread.

In addition, such as and are particularly transcription-dependent.

Therefore, drug may also work well for these too, especially where they have become resistant to other treatments, the researchers suggested.



(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, April 11 2018. 13:28 IST